The Hindu Business Line : US co to develop, sell Ranbaxy's statin

Advertisement

New Delhi March 1 Pharmaceutical Product Development Inc (PPD) has acquired the rights to develop, manufacture and market Ranbaxy Laboratories' novel anti-cholesterol statin.

PPD, the US-based contract research organisation, will conduct additional pre-clinical studies and file an investigational new drug application with the US Food and Drug Administration in April.

Ranbaxy claims that early pre-clinical studies of the second compound from Ranbaxy's New Drug Discovery Research division have suggested that the statin offers improved safety profile over currently marketed statins.

Under the terms of the license agreement, Ranbaxy will receive `milestone payments' when specified clinical events occur, and will also receive royalties on sales, when and if the drug gets marketing approval. The company will also have co-marketing rights for India. PPD will bear all costs and expenses of the development, including pre-clinical and clinical studies, and commercialisation of the drug.

"We are pleased to partner with PPD in taking this potential drug forward promising superior treatment for dyslipidemia and related areas," said Mr Malvinder Singh, CEO and MD, Ranbaxy, in an official statement.

More Stories on : IPR | Pharmaceuticals | Ranbaxy Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Skoda announces price cut; Hyundai plans to raise prices

Dividend distribution tax: It's better off being foreign branch office

US co to develop, sell Ranbaxy's statin

Himatsingka buys 70% stake in Italian co

Kuwait group to set up 5-star hotel in Kochi

Finnish nod for Aurobindo unit

Tie-up for new gas pipeline project

No change in RIL's petro prices

Oil India IPO likely by Oct

Oil marketing firms losing Rs 100 cr a day

Tata Motor's UV range posts highest sales in February

Hero Honda sales up 11.8% in Feb

M&M Feb sales up 19.2%